Last update 12 Dec 2024
TQB-2868
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms TQB 2868, TQB-2868, TQB2868 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with TQB-2868TQB2868注射液联合安罗替尼胶囊与化疗一线治疗转移性胰腺癌的单臂、开放、Ⅱ期临床研究
[Translation] A single-arm, open-label, phase II clinical study of TQB2868 injection combined with anlotinib capsules and first-line chemotherapy in the treatment of metastatic pancreatic cancer
A single-arm, open-label, phase ? clinical trial of TQB2868 injection combined with anlotinib capsule and chemotherapy as first-line treatment for metastatic pancreatic cancer
TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ Study
100 Clinical Results associated with TQB-2868
Login to view more data
100 Translational Medicine associated with TQB-2868
Login to view more data
100 Patents (Medical) associated with TQB-2868
Login to view more data
100 Deals associated with TQB-2868
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Phase 2 | CN | 08 Mar 2024 | |
| Uterine Cervical Cancer | Phase 2 | CN | 01 Aug 2023 | |
| Hepatocellular Carcinoma | Phase 2 | CN | 31 Mar 2023 | |
| Locally Advanced Malignant Neoplasm | Phase 1 | CN | 27 Apr 2022 | |
| Advanced cancer | Phase 1 | CN | 20 Apr 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free